JamesMelvinRajanMD

Nephrology • Canton, OH

Interventional Nephrology

Physician

Join to view full profile

Dr. Rajan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rajan's full profile

Already have an account?

Office
4610 Hills and Dales Rd NW
Canton, OH 44708
Phone+1 330-649-9400

Fax+1 330-649-8059

Summary

Dr. James Rajan is a nephrologist in Canton, OH and is affiliated with multiple hospitals in the area, including Mercy Medical Center, Affinity Medical Center, Alliance Community Hospital, and Aultman Hospital. He received his medical degree from Ross University School of Medicine and has been in practice 16 years. He specializes in interventional nephrology and is experienced in acute renal failure and chronic renal failure.

Education & Training

Ohio State University HospitalFellowship, Nephrology, 2004 - 2006
Canton Medical Education Foundation/NEOMEDResidency, Internal Medicine, 2001 - 2004
Ross University School of MedicineClass of 2001

Certifications & Licensure

OH State Medical License 2001 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Nephrology

Clinical Trials

Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia Start of enrollment: 2014 Jun 01
Terminated
Phase 2
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD) Start of enrollment: 2013 Oct 31
Completed
Phase 2
Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia Start of enrollment: 2020 Nov 20
Completed
Phase 4
Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients Start of enrollment: 2006 Jan 01
Completed
Phase 1
HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis Start of enrollment: 2019 Apr 29
Active, not recruiting
Phase 1
Phase 2 Study With SNF472 in Calciphylaxis Patients Start of enrollment: 2016 May 01
Completed
Phase 2
A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1) Start of enrollment: 2018 Feb 20
Completed
Phase 3
Vest Prevention of Early Sudden Death Trial and VEST Registry Start of enrollment: 2008 Jul 01
Completed
Not Applicable
Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa Start of enrollment: 2019 Jan 31
Completed
Phase 2
Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents Start of enrollment: 2017 May 02
Terminated
Phase 2
Join now to see all